Hydrogen sulfide and the metabolic syndrome

Kaushik M. Desai, Tuanjie Chang, Ashley Untereiner, Lingyun Wu

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The metabolic syndrome is a group of abnormalities including obesity, high blood pressure, hyperinsulinemia, high blood glucose levels and hyperlipidemia that together greatly increase the risk of developing cardiovascular disease and Type 2 diabetes. Hydrogen sulfide (H 2S) is a vasodilatory gasotransmitter mediator in the cardiovascular system, proposed as an endothelium-derived relaxing factor. A lack of H 2S and its synthesizing enzyme, cystathionine -lyase, in the vasculature causes hypertension, whereas an increase in the pancreas reduces insulin secretion. Thus, research is making inroads to determine whether H 2S is involved in the pathogenesis of the metabolic syndrome. Several laboratories are synthesizing and testing clinically used drugs that release H 2S. Some of these compounds are being tested for effectiveness in the metabolic syndrome.

Original languageEnglish (US)
Pages (from-to)63-73
Number of pages11
JournalExpert Review of Clinical Pharmacology
Volume4
Issue number1
DOIs
StatePublished - Jan 2011
Externally publishedYes

Fingerprint

Hydrogen Sulfide
Gasotransmitters
Cystathionine
Hypertension
Endothelium-Dependent Relaxing Factors
Lyases
Hyperinsulinism
Cardiovascular System
Hyperlipidemias
Type 2 Diabetes Mellitus
Blood Glucose
Pancreas
Cardiovascular Diseases
Obesity
Insulin
Enzymes
Research

Keywords

  • diabetes
  • hydrogen sulfide
  • hypertension
  • metabolic syndrome
  • obesity

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Hydrogen sulfide and the metabolic syndrome. / Desai, Kaushik M.; Chang, Tuanjie; Untereiner, Ashley; Wu, Lingyun.

In: Expert Review of Clinical Pharmacology, Vol. 4, No. 1, 01.2011, p. 63-73.

Research output: Contribution to journalArticle

Desai, KM, Chang, T, Untereiner, A & Wu, L 2011, 'Hydrogen sulfide and the metabolic syndrome', Expert Review of Clinical Pharmacology, vol. 4, no. 1, pp. 63-73. https://doi.org/10.1586/ecp.10.133
Desai, Kaushik M. ; Chang, Tuanjie ; Untereiner, Ashley ; Wu, Lingyun. / Hydrogen sulfide and the metabolic syndrome. In: Expert Review of Clinical Pharmacology. 2011 ; Vol. 4, No. 1. pp. 63-73.
@article{d53561b7c29a4e50bad2eb0f139c64bd,
title = "Hydrogen sulfide and the metabolic syndrome",
abstract = "The metabolic syndrome is a group of abnormalities including obesity, high blood pressure, hyperinsulinemia, high blood glucose levels and hyperlipidemia that together greatly increase the risk of developing cardiovascular disease and Type 2 diabetes. Hydrogen sulfide (H 2S) is a vasodilatory gasotransmitter mediator in the cardiovascular system, proposed as an endothelium-derived relaxing factor. A lack of H 2S and its synthesizing enzyme, cystathionine -lyase, in the vasculature causes hypertension, whereas an increase in the pancreas reduces insulin secretion. Thus, research is making inroads to determine whether H 2S is involved in the pathogenesis of the metabolic syndrome. Several laboratories are synthesizing and testing clinically used drugs that release H 2S. Some of these compounds are being tested for effectiveness in the metabolic syndrome.",
keywords = "diabetes, hydrogen sulfide, hypertension, metabolic syndrome, obesity",
author = "Desai, {Kaushik M.} and Tuanjie Chang and Ashley Untereiner and Lingyun Wu",
year = "2011",
month = "1",
doi = "10.1586/ecp.10.133",
language = "English (US)",
volume = "4",
pages = "63--73",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Hydrogen sulfide and the metabolic syndrome

AU - Desai, Kaushik M.

AU - Chang, Tuanjie

AU - Untereiner, Ashley

AU - Wu, Lingyun

PY - 2011/1

Y1 - 2011/1

N2 - The metabolic syndrome is a group of abnormalities including obesity, high blood pressure, hyperinsulinemia, high blood glucose levels and hyperlipidemia that together greatly increase the risk of developing cardiovascular disease and Type 2 diabetes. Hydrogen sulfide (H 2S) is a vasodilatory gasotransmitter mediator in the cardiovascular system, proposed as an endothelium-derived relaxing factor. A lack of H 2S and its synthesizing enzyme, cystathionine -lyase, in the vasculature causes hypertension, whereas an increase in the pancreas reduces insulin secretion. Thus, research is making inroads to determine whether H 2S is involved in the pathogenesis of the metabolic syndrome. Several laboratories are synthesizing and testing clinically used drugs that release H 2S. Some of these compounds are being tested for effectiveness in the metabolic syndrome.

AB - The metabolic syndrome is a group of abnormalities including obesity, high blood pressure, hyperinsulinemia, high blood glucose levels and hyperlipidemia that together greatly increase the risk of developing cardiovascular disease and Type 2 diabetes. Hydrogen sulfide (H 2S) is a vasodilatory gasotransmitter mediator in the cardiovascular system, proposed as an endothelium-derived relaxing factor. A lack of H 2S and its synthesizing enzyme, cystathionine -lyase, in the vasculature causes hypertension, whereas an increase in the pancreas reduces insulin secretion. Thus, research is making inroads to determine whether H 2S is involved in the pathogenesis of the metabolic syndrome. Several laboratories are synthesizing and testing clinically used drugs that release H 2S. Some of these compounds are being tested for effectiveness in the metabolic syndrome.

KW - diabetes

KW - hydrogen sulfide

KW - hypertension

KW - metabolic syndrome

KW - obesity

UR - http://www.scopus.com/inward/record.url?scp=78650476738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650476738&partnerID=8YFLogxK

U2 - 10.1586/ecp.10.133

DO - 10.1586/ecp.10.133

M3 - Article

C2 - 22115349

AN - SCOPUS:78650476738

VL - 4

SP - 63

EP - 73

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 1

ER -